Navigation Links
SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO

BOTHELL, Wash., Feb. 2 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced that the board of directors has appointed Bruce S. Morra, Ph.D., M.B.A., to serve as president and chief executive officer. Dr. Morra has served as a member of the SCOLR Pharma board of directors since August 2007.

Michael N. Taglich, Chairman of SCOLR Pharma's board of directors, said, "We are very pleased that Dr. Morra has agreed to become SCOLR Pharma's CEO. Since Dr. Morra's appointment to the board, he has been an able and trusted advisor. Given our longstanding belief that SCOLR's success will stem from maximizing opportunities for our proprietary CDT(R) technology in the pharmaceutical and over-the-counter arena, Dr. Morra's level of experience earned as an executive at numerous specialty pharmaceutical and healthcare companies coupled with his strategic alliance and business development expertise, makes him the right executive to assume leadership of our Company."

Dr. Morra has extensive experience in the pharmaceutical, medical device, biotechnology and polymers industries. Since 1998, Dr. Morra has been a Board Member and consultant for various public and private life science companies. He previously served as the President of West Pharmaceutical Services Drug Delivery and Contract Clinical Research businesses. Prior to this, Dr. Morra held several senior executive management positions including as Chief Business Officer of Progenitor Cell Therapy, as President, COO and CFO of Biopore Corporation and Polygenetics, Inc., as President, COO and Founder of Flamel Technologies, Inc's U.S. subsidiary, and as President of ISP Filters, a subsidiary of GAF Corporation. He received his B.S.E in Chemical Engineering from Princeton, a Ph.D. in Polymer Science and Engineering and an M.B.A. from the University of Massachusetts at Amherst.

Commenting on his appointment, Dr. Morra, said, "The board has a great deal of confidence in the executive team and in all of the SCOLR employees. I am honored to assume the role of CEO of SCOLR, and I look forward to leading the Company. SCOLR has made important advancements in its two primary programs, ibuprofen and pseudoephedrine, and is in a great position to build on its innovative CDT technology and development pipeline. I welcome the challenges and opportunities ahead as we work to advance the Company's strategy to expand our business and move our product candidates through the FDA process towards the market place."

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.368.1050 or visit

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements related to the timing and success of our products under development and the potential for alliances. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to successfully develop new formulations and complete research and development, including pre-clinical and clinical studies, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products and we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

    Investor Relations:
    Cameron Associates
    Kevin McGrath

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
2. SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern
3. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
4. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
5. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
6. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
7. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
8. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
9. Why Do Drugs Cost So Much? and why are we so darn sick?: New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health
10. China Biopharma, Inc. Issues Corporate Information Update
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: